Alkylating agents

1 marketed 1 in Phase 3 1 in Phase 2

This page covers all Alkylating agents drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds.

Marketed (1)

Busulfan/Cyclophosphamide · Tel-Aviv Sourasky Medical Center · Oncology
Busulfan and cyclophosphamide are alkylating agents that damage DNA and suppress bone marrow function, used together as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation.

Phase 3 pipeline (1)

Busulphan plus Cyclophosphamide · Gruppo Italiano Trapianto di Midollo Osseo · Oncology
Busulphan and cyclophosphamide are alkylating agents that damage DNA in cancer cells and bone marrow cells, used together as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation.

Phase 2 pipeline (1)

Etoposide, carboplatin, melphalan, cisplatin, thiotepa · Gustave Roussy, Cancer Campus, Grand Paris · Oncology
Etoposide, carboplatin, melphalan, cisplatin, and thiotepa are chemotherapeutic agents that work by interfering with DNA replication and cell division, ultimately leading to cell death.